

## BIOSYNTHETIC STUDIES ON VALIDAMYCINS

I.  $^1\text{H}$  AND  $^{13}\text{C}$  NMR ASSIGNMENTS OF VALIDAMYCIN A<sup>†</sup>WEN-ZAO JIN<sup>††</sup>, KENNETH L. RINEHART, Jr.\* and TATSUSHI TOYOKUNI454 Roger Adams Laboratory, University of Illinois at Urbana-Champaign,  
1209 W. California, Urbana, IL 61801, U.S.A.

(Received for publication October 6, 1986)

The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of validamycin A have been assigned by use of 2D homo-nuclear correlation spectroscopy for protons, and off-resonance decoupling, single frequency off-resonance decoupling, and comparison studies with model compounds for carbons. Effects of pH on carbon chemical shifts have also been studied.

Validamycin A is the major and most active component of the validamycin complex isolated in 1971 by IWASA *et al.*<sup>1)</sup> from *Streptomyces hygroscopicus* var. *limoneus*. The antibiotic is widely used in the Orient for the treatment of sheath blight disease of rice plants.

The structure of validamycin A, first proposed by HORII and KAMEDA,<sup>2)</sup> was recently revised by SUAMI *et al.*,<sup>3,4)</sup> on the basis of synthetic studies, to the 4-*O*-glucosyl structure shown in Scheme 1. Validamycin A (1) is characterized by the novel structure of its aglycone, validoxylamine A (2), which consists of two aliphatic  $\text{C}_7$  units, validamine and valienamine (3 and 4, respectively). These units share a single nitrogen atom and differ from one another only in their degrees of unsaturation. Both of them constitute potential "*m*- $\text{C}_7\text{N}$ " units<sup>5,6)</sup> and are, thus, particularly intriguing in connection with our continuing biosynthetic studies on *m*- $\text{C}_7\text{N}$  antibiotics.<sup>7)</sup>

Since we have used  $^{13}\text{C}$  NMR spectroscopy for multi-labeled *m*- $\text{C}_7\text{N}$  antibiotics in studies on the conversion of  $^{13}\text{C}$ -enriched precursors<sup>8)</sup> and expected to do so for validamycin, complete assignment of the  $^{13}\text{C}$  resonances in spectra of 1 and 2 was a first priority. In the present paper the  $^{13}\text{C}$  NMR assignments of 1 and 2, as well as their  $^1\text{H}$  NMR assignments, are reported.

### Results and Discussion

#### Assignment of $^1\text{H}$ NMR Spectra

For a single frequency off-resonance decoupling (SFORD) experiment, it is necessary to assign the individual signals in the  $^1\text{H}$  NMR spectrum. In aminocyclitol antibiotics, however, complete assignment of ring protons, other than anomeric protons, is always formidable<sup>†††</sup> due to the severe overlap of spin-coupled multiplets of these protons.


The spectra for 1 and 2 were measured at 500 MHz, to separate nearly all the resonances (Table 1). More than half of the peaks in the spectrum of 2 could be assigned readily from chemical shift and coupling constant considerations; this was true of protons 2' (olefinic), 5, 6<sub>ax</sub>, 6<sub>eq</sub>, 7a and 7b

<sup>†</sup> Dedicated to Professor TETSUO SUAMI, our long-term collaborator and friend and an inspiring teacher at Keio University, on the occasion of his retirement from Keio University.

<sup>††</sup> On leave of absence, 1981~1983, from the Institute of Antibiotics, Chinese Academy of Medical Sciences, Beijing.

<sup>†††</sup> Recently, the  $^1\text{H}$  NMR spectrum of neomycin B was assigned completely by use of 2D *J*-resolved spectroscopy at 400 MHz.<sup>9)</sup>

Scheme 1. Structures of validamycin A and related compounds.



(aliphatic), 4' (allylic), and 7'a and 7'b (split AB quartet). Moreover, H-4 is assigned by its coupling constant to H-5 (11.0 Hz), H-1 by its coupling constants to H-6<sub>ax</sub> and H-6<sub>eq</sub> (3.0 and 4.0 Hz), and H-1' by its coupling constant to H-2' (5.0 Hz). There was some overlap of multiplets in the region near 3.7 ppm (Fig. 1), where the assignments were greatly facilitated by employing 2D homonuclear correlation spectroscopy (COSY).<sup>10,11</sup> Contour plots of the COSY maps for 2 (and 1) are shown in Fig. 1. Four hydroxymethine protons (H-2, H-3, H-5' and H-6') for 2 appear in the range  $\delta$  3.6~3.7 ppm and make up complex multiplets. The coupling constants for two protons, each a doublet of doublets, at  $\delta$  3.62 ppm ( $J=9.5$  and 4.0 Hz) and 3.68 ppm ( $J=10.0$  and 5.0 Hz), suggest that each of these signals is due to an axial proton split by vicinal axial and equatorial protons.<sup>12</sup> In addition, the contour map for 2 clearly identifies the coupling between H-1 and H-2 and between H-1' and H-6'. Therefore, these two peaks can be assigned to H-2 ( $\delta$  3.62 ppm) and H-6' ( $\delta$  3.68 ppm). However, resonances for H-3 and H-5' appearing around  $\delta$  3.65 ppm are not completely dispersed, which leaves their assignments ambiguous.

For 1, some of the assignments can be made from chemical shift and coupling constant considerations—H-5, H-6<sub>ax</sub>, H-6<sub>eq</sub>, H-7a, H-7b, H-2', H-4', H-7'a and H-7'b. In addition, starting with the anomeric proton H-1'' at  $\delta$  4.59 ppm, all the resonances due to the glucose protons are assigned completely (Fig. 1). The observed coupling constants agree with the assignment. Similarly,

Table 1.  $^1\text{H}$  NMR data for validamycin A (1) and validoxylamine A (2).

Proton	$\delta$ , m, (J) <sup>a</sup>	
	1 (free base, pH 7.6)	2 (free base, pH 8.0)
H-1	3.49 br s	3.33 td (4.0, 3.0)
H-2	3.76 dd (9.5, 3.5)	3.62 dd (9.5, 4.0)
H-3	3.81 dd (10.0, 9.5)	~3.65 <sup>c</sup>
H-4	3.60 dd (10.0, 8.0)	3.32 dd (11.0, 8.5)
H-5	2.16 m	1.94 dddd (13.0, 11.0, 6.0, 4.0)
H-6 <sub>ax</sub>	1.54 br t (~14.0)	1.36 ddd (14.5, 13.0, 3.0)
H-6 <sub>eq</sub>	2.10 m	2.01 dt (14.5, 4.0)
H-7a	3.84 dd (11.0, 4.0)	3.71 dd (11.0, 6.0)
H-7b	3.86 dd (11.0, 4.5)	3.79 dd (11.0, 4.0)
H-1'	3.66 br s	3.43 t (5.0)
H-2'	6.07 dq (5.0, 1.5)	6.08 dq (5.0, 1.5)
H-4'	4.16 br ddd (7.0, 1.5, 1.0)	4.14 br d (~7.0)
H-5'	3.76 dd (10.0, 7.0)	~3.65 <sup>c</sup>
H-6'	~3.80 <sup>b</sup>	3.68 dd (10.0, 5.0)
H-7'a	4.22 br d (13.5)	4.18 br d (13.5)
H-7'b	4.31 ddd (13.5, 2.5, 1.5)	4.29 ddd (13.5, 2.5, 1.5)
H-1''	4.59 d (8.0)	
H-2''	3.40 dd (9.5, 8.0)	
H-3''	3.58 t (9.5)	
H-4''	3.49 dd (10.0, 9.5)	
H-5''	3.55 ddd (10.0, 5.5, 2.5)	
H-6''a	3.80 dd (12.5, 5.5)	
H-6''b	3.97 dd (12.5, 2.5)	

<sup>a</sup>  $\delta$  in ppm downfield from 3-(trimethylsilyl)propionate (TSP); multiplicity; (J in Hz).

<sup>b</sup> The peak was overlapping those of H-3 and H-6'a so that unambiguous assignment could not be made.

<sup>c</sup> The peaks were overlapping and the assignments thus remained obscure.

based on the signals of H-2' at  $\delta$  6.07 ppm and H-5 at  $\delta$  2.16 ppm, the spin coupling network of the protons for the valienamine and validamine units are identified. However, unequivocal assignment of H-6' was not possible due to overlap with the H-3 and H-6''a signals.

The coupling constants indicate that the validamine and valienamine units adopt energetically favorable chair and half-chair conformations,<sup>13</sup> respectively, in both **1** and **2**.

It is obvious from Table 1 that the introduction of glucose causes downfield shifts (0.07~0.28 ppm) for the protons in the validamine unit. Surprisingly, H-1', in the valienamine unit of **1** and thus rather remote from the glucose-bearing carbon (C-4), is also shifted downfield by 0.23 ppm relative to its signal in **2**.


#### Assignment of $^{13}\text{C}$ NMR Spectra

Since the effects of pH on the carbon shifts in aminocyclitol antibiotics are well known,<sup>14</sup> the spectra were recorded together with pH measurements; the results are found in Table 2.

#### Validamine (3), Valienamine (4) and Their *N*-Methyl Derivatives (5 and 6)

First,  $^{13}\text{C}$  NMR spectra of **3** and **4**, which are components of the antibiotic, were assigned. Carbons bearing nitrogen atoms (C-1 and C-1'), methylene and methine carbons (C-6 and C-5) and olefinic carbons (C-2' and C-3') were easily assigned on the basis of chemical shifts.

Hydroxymethine carbons (C-2, C-3 and C-4) in **3** were tentatively distinguished on the basis of substituent effects. Thus, it can be argued that the carbon  $\beta$  to an alkyl group (C-4) should appear

Fig. 1. COSY maps for validamycin A and validoxylamine A (D<sub>2</sub>O).

at the highest field, and that the carbon  $\beta$  to nitrogen (C-2) should be at higher field than that  $\beta$  to oxygen (C-3).<sup>†</sup>

Applying the same argument to **4**, C-6' should appear at higher field than C-5'. Since  $\Delta\delta$  (pH shift) for the carbon  $\beta$  to nitrogen should be the largest ( $\sim 3$  ppm)<sup>15)</sup> among those for the saturated  $\beta$ -,  $\gamma$ - and  $\delta$ -carbons, the signal at  $\delta$  67.9 ppm (pH 3.5) can be assigned to C-6',  $\beta$  to nitrogen, which is found at 70.2 ppm for the free base. However, unambiguous assignments for C-4' and C-5' can not be made because of the similarity in their chemical shifts.

As model compounds for **1** and **2**, mono-*N*-methyl derivatives of validamine and valienamine (**5**

<sup>†</sup> Comparison of the reported spectra of *N*-methylcyclohexylamine<sup>15)</sup> and cyclohexanol<sup>16)</sup> supports the latter argument.

Table 2.  $^{13}\text{C}$  NMR data for validamycin A and related compounds.

Carbon	$\delta$ (ppm from TSP)												
	3		5		4		6		2		7	1	
	pH 8.5 <sup>a</sup>	pH 4.0	pH 8.5 <sup>a</sup>	pH 3.0	pH 8.5 <sup>a</sup>	pH 3.5	pH 8.5 <sup>a</sup>	pH 3.5	pH 8.0 <sup>a</sup>	(m) <sup>b</sup>		Change(s) on irradiating H-X	pH 7.6 <sup>a</sup>
C-1	50.4	52.1	59.5	60.4					56.4	(d)	H-1 <sup>d</sup> → s	56.2	(d)
C-2	74.6 <sup>c</sup>	70.9	74.3	71.1					76.0	(d)		75.6	(d)
C-3	74.8 <sup>c</sup>	74.6 <sup>c</sup>	75.4 <sup>c</sup>	74.9					76.8	(d)		75.2	(d)
C-4	74.2 <sup>c</sup>	72.9 <sup>c</sup>	74.3 <sup>c</sup>	72.8					75.9	(d)	H-1 <sup>d</sup> → signal shape changed	86.8	(d)
C-5	38.7	38.8	38.8	38.8					40.5	(d)		39.9	(d)
C-6	30.3	26.8	26.3	23.8					29.4	(t)		29.4	(t)
C-7	63.3	62.4	63.4	62.4					65.0	(t)		64.3	(t)
C-1'					49.9	50.5	57.5	57.7	54.8	(d)	H-1' → s	54.9	(d)
C-2'					123.1	116.7	123.3	114.2	125.5	(d)		125.5	(d)
C-3'					141.8	147.0	140.7	147.9	141.6	(s)		141.7	(s)
C-4'					72.5 <sup>c</sup>	71.9 <sup>c</sup>	72.4 <sup>c</sup>	71.5 <sup>c</sup>	73.9	(d)	H-4' → s	74.0	(d)
C-5'					72.9 <sup>c</sup>	72.9 <sup>c</sup>	73.5 <sup>c</sup>	72.7 <sup>c</sup>	75.9	(d)		76.2	(d)
C-6'					70.2	67.9	70.3	67.4	71.8	(d)		72.0	(d)
C-7'					62.2	62.2	62.5	62.0	64.0	(t)	A center of H-7'a, b → s	64.1	(t)
C-1''												105.8	105.3 (d)
C-2''												75.7	75.9 (d)
C-3''												78.3 <sup>c</sup>	78.1 (d)
C-4''												72.2	72.0 (d)
C-5''												78.5 <sup>c</sup>	78.5 (d)
C-6''												63.3	63.0 (t)
NCH <sub>3</sub>			34.1	32.6				34.0	31.8				
OCH <sub>3</sub>												59.8	

<sup>a</sup> Compounds in aqueous solution were passed through a short column of Amberlite IRA 400 (OH<sup>-</sup>) resin and dried *in vacuo* overnight with sodium hydroxide pellets in order to obtain their free bases.

<sup>b</sup> Multiplicity in off-resonance decoupled spectra.

<sup>c</sup> Signals may be interchanged in the column where they appear.

<sup>d</sup> The signal is partially overlapping with H-4 in the <sup>1</sup>H NMR spectrum.

and **6**, respectively) were prepared (see Experimental section) and their  $^{13}\text{C}$  NMR spectra were measured. Again, the assignments for hydroxymethine carbons were made tentatively, using the same criteria as above.

Upon *N*-methylation,  $\alpha$ -carbons (C-1 and C-1') show the expected downfield shifts, by 9.1 and 7.6 ppm, respectively, while the remaining carbons show less effect, except C-6, which shifts upfield by 4.0 ppm.

Interestingly, protonation causes an unusually large downfield shift in valienamine and its *N*-methyl derivative (5.2 ppm in **4** and 7.2 ppm in **6**) for C-3',  $\gamma$  to nitrogen. This seems to be explicable in terms of an allylic effect, which suggests that a positive charge introduced by protonation of an allylic nitrogen atom could polarize a  $\pi$ -bond, resulting in decreased electron density around C-3'.<sup>†</sup>

It is also noteworthy that the  $\alpha$ -carbons (C-1 and C-1') shift slightly downfield upon protonation, while the *N*-methyl carbons, also  $\alpha$  to nitrogen, shift upfield (*ca.* 1.5 ppm).

Comparing the chemical shifts of **3** and **4** and of **5** and **6**, it can be deduced that the carbons in the valienamine unit appear at 0.5~4.0 ppm higher field than corresponding carbons in the validamine unit.<sup>18,19)</sup>

#### Validoxylamine A (2)

Assignments were made by use of off-resonance decoupling and SFORD experiments and by comparison of the  $^{13}\text{C}$  NMR spectrum with those of **5** and **6**.

The olefinic carbons (C-2' and C-3') and the methylene (C-6) and methine (C-5) carbons bearing no oxygen are also easily recognized and distinguished by their off-resonance patterns.

The hydroxymethyl carbons (C-7 and C-7') were identified by the off-resonance decoupled spectrum and by the triplet  $\rightarrow$  singlet transformation undergone by the higher field signal (C-7') when the center (at *ca.* 4.2 ppm) of the AB quartet due to the two H-7' protons was irradiated.


Differentiation of C-1 and C-1', the only nitrogen-bearing carbons, is also based on SFORD studies. Irradiation of H-1' (near 3.4 ppm) caused a doublet  $\rightarrow$  singlet conversion for the higher field signal (54.8 ppm). Similarly, irradiation of H-1 (near 3.3 ppm), partially overlapping H-4 in the  $^1\text{H}$  NMR spectrum, converted the lower field doublet (56.4 ppm) to a singlet, and there was also a change in the shape and an enhancement in the intensity of the 75.9-ppm resonance,<sup>††</sup> which could then be attributed to C-4. SFORD at H-4' (near 4.15 ppm) afforded a doublet  $\rightarrow$  singlet conversion of the 73.9-ppm resonance, assigning the C-4' carbon.

It was difficult to apply SFORD for the assignment of the remaining hydroxymethine carbons (C-2, C-3, C-5' and C-6') because the chemical shifts of their attached protons (H-2, H-3, H-5' and H-6') were nearly identical. The above assignments for C-1, C-1'; C-4, C-4'; and C-7, C-7' indicate that the carbons of the valienamine unit appear upfield relative to the corresponding carbons in the validamine unit, just as they do in the monomers **3**~**6**. If this correlation is considered, the resonance at  $\delta$  71.8 ppm should belong to a valienamine carbon and that at  $\delta$  76.8 ppm to a validamine carbon. Moreover, consideration of the effect of the adjacent substituents allows the assignment of the 71.8-ppm signal to C-6',  $\beta$  to nitrogen, and of the 76.8-ppm resonance to C-3,  $\beta$  to oxygen. By comparing

<sup>†</sup> DAVIES *et al.*<sup>17)</sup> listed  $^{13}\text{C}$  chemical shifts for sisomicin as free base and at pH 1.5. A similar allylic effect upon protonation is seen in their data (5.2 ppm for C-4' in their table).

<sup>††</sup> A singlet at  $\delta$  75.9 ppm in the noise-decoupled spectrum becomes two closely overlapping doublets in the off-resonance decoupled spectrum. This indicates that the 75.9-ppm singlet consists of two methine carbon signals.

Fig. 2. Protonation effects for (a) validamycin A and (b) validoxylamine A. Parenthesis indicates protonation shifts,  $\Delta = \delta_{\text{pH } 5.5} - \delta_{\text{free base}}$  for validamycin A and  $\Delta = \delta_{\text{pH } 5.0} - \delta_{\text{free base}}$  for validoxylamine A. Chemical shift:  $\delta$ , ppm from TSP.



the chemical shifts of C-2 and C-5' in **3** and **5** as well as in **4** and **6**, the higher field signal ( $\delta$  75.9 ppm) can be tentatively assigned to C-5' and the signal at  $\delta$  76.0 ppm to C-2. The protonation shift shown in Fig. 2 confirms the above assignments, showing that protonation causes upfield shifts of about 3 ppm for C-2 and C-6',  $\beta$  to nitrogen, and of about 1.2 ppm for C-3 and C-5',  $\gamma$  to nitrogen.

Like *N*-methylation of **3** and **4**, formation of an imino linkage between **3** and **4** produced significant downfield shifts for C-1 and C-1' (6.0 and 4.9 ppm, respectively),  $\alpha$  to nitrogen, with smaller effects (0.9 to 3.0 ppm) on other carbons.

As expected from the shifts in **3**, **4**, **5** and **6**, protonation of **2** resulted in sizable downfield shifts for the  $\alpha$ -carbons (4.1 ppm for C-1 and 4.4 ppm for C-1') and the  $\gamma$ -olefinic carbon (7.0 ppm for C-3').

#### Validamycin A (**1**)

The results obtained for validoxylamine A facilitated the assignment of the  $^{13}\text{C}$  NMR spectrum of **1**. Assignment of the glucose carbons was based on the chemical shifts for methyl  $\beta$ -D-glucopyranoside (**7**).<sup>†</sup> Comparison of validoxylamine A and validamycin A spectra identifies the C-4

<sup>†</sup> The assignment of methyl  $\beta$ -D-glucopyranoside was made by reference to the review article.<sup>20)</sup>

carbon as that bearing the glucose unit, in agreement with the revised structure.<sup>3)</sup>

The assignments shown in Table 2 are supported by considering glycosidation effects. Thus, glucoside formation produces a 10.9-ppm downfield shift for the  $\alpha$ -carbon (C-4) and 1.6-ppm and 0.6-ppm upfield shifts for the  $\beta$ -carbons (C-3 and C-5, respectively). The  $\gamma$ -carbons (C-2 and C-6) shift less than 0.4 ppm. These shifts are in good agreement with the results previously reported for bluensomycin.<sup>2,1)</sup>

Although the protonation effect observed was similar to that in validoxyamine A, it must be mentioned that the carbons C-1, C-1', C-2, C-2', C-3, C-3', C-6 and C-6' exhibited significant line-broadening at pH 6.8 and 6.2, probably due to a rapid equilibration between protonated and non-protonated forms.

## Experimental

### General

One-dimensional and COSY  $^1\text{H}$  NMR spectra of validamycin A and validoxyamine A were recorded by S. A. MIZSAK at The Upjohn Company, Kalamazoo, MI, on a Bruker WM-500 spectrometer in deuterium oxide ( $\text{D}_2\text{O}$ ) containing sodium 3-(trimethylsilyl)propionate (TSP) as an internal standard.  $^1\text{H}$  NMR spectra of other compounds and  $^{13}\text{C}$  NMR spectra were measured on a Nicolet NT-360 spectrometer in deuteriochloroform ( $\text{CDCl}_3$ ) or  $\text{D}_2\text{O}$ . Chemical shift standards were TMS ( $\text{CDCl}_3$ ) and TSP ( $\text{D}_2\text{O}$ ). The pH was adjusted with either 1 M hydrochloric acid or 0.5 M sodium hydroxide and measured with pHyrion papers (3.0 to 5.5, 6.0 to 8.0, and 8.0 to 9.5). Fast atom bombardment mass spectra (FAB-MS) were obtained using a VG Analytical 7070E spectrometer. TLC was performed on precoated Silica gel 60F<sub>254</sub> plates (Merck, Darmstadt; 0.25-mm thickness). Silica gel used for column chromatography was purchased from Brinkmann (particle mesh size 0.05 to 0.2 mm). Solutions were evaporated at 50°C under reduced pressure.

### Production of Validamycin A (1)

*Streptomyces hygroscopicus* var. *limoneus* was grown in a seed medium (Tryptone 0.5%, yeast extract 0.3%, D-glucose 0.3% and tap water 100 ml) in a 500-ml Erlenmeyer flask at 28°C on a rotary shaker at 20 rpm for 2 days. The seed (5 ml) was then used to inoculate 100-ml portions of production medium (D-glucose 1.0%, soluble starch 5.0%, peptone 1.5%, corn gluten meal 3.0%, NaCl 0.5%,  $\text{CaCO}_3$  1.0% and distilled water) in a 500-ml flask. The pH of the production medium was adjusted to 9.3~9.5 with NaOH before sterilization. Cultures were incubated at 28°C on a rotary shaker for 7 days. The antibiotic was isolated according to the reported procedure<sup>22)</sup> and purified further by chromatography over Dowex 1-X2 ( $\text{OH}^-$ ) with water, which gave a colorless powder after solidification from ethanol: NMR, see Tables 1 and 2, Figs. 1 and 2; FAB-MS  $m/z$  498 ( $\text{M}+\text{H}$ ).

### Validoxyamine A (2)

Validamycin A (1) was hydrolyzed according to the reported procedure<sup>23)</sup> to give 2 in 80% yield: NMR, see Tables 1 and 2, Figs. 1 and 2; FAB-MS  $m/z$  336 ( $\text{M}+\text{H}$ ).

### Racemic Validamine (3)

Racemic 2,3:4,7-di-*O*-isopropylidene-(1,2,4/3,5)-2,3,4-trihydroxy-5-(hydroxymethyl)cyclohexylamine (di-*O*-isopropylidenevalidamine, 8,<sup>24)</sup> 25 mg) was treated with 1 M hydrochloric acid (1 ml) at room temperature overnight. The mixture was neutralized with Amberlite IRA-400 ( $\text{OH}^-$ ) resin. After the resin had been removed by filtration, the filtrate was evaporated to give a pale yellow syrup (18 mg, 98%), which was purified by passage through a short column of Dowex 1-X2 ( $\text{OH}^-$ , 100~200 mesh) resin with water. The ninhydrin-positive fractions were combined and evaporated to give 3 (15 mg, 86%) as a colorless syrup. FAB-MS gave  $m/z$  178 ( $\text{M}+\text{H}$ ).

### Racemic Valienamine (4)

According to the previously reported procedure,<sup>25)</sup> racemic 1,2:3,7-di-*O*-isopropylidene-(1,3,6/2)-



6-azido-4-hydroxymethyl-4-cyclohexene-1,2,3-triol (**9**, 20 mg) was reduced with hydrogen sulfide to give a yellow solid, which was chromatographed over silica gel with toluene - ethanol (1 : 1). The ninhydrin-positive fractions were combined and evaporated to give racemic 4,7:5,6-di-*O*-isopropylidene-(1,4,6/5)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexenylamine (di-*O*-isopropylidenevalienamine, **12**, 17 mg, 90%) as a colorless foam, which was then treated with 1 M hydrochloric acid in the same manner as described for the preparation of **3**. Chromatography over Dowex 1-X2 (OH<sup>-</sup>, 100~200 mesh) with water yielded **4** (10 mg, 82% from **9**) as a colorless syrup. FAB-MS gave *m/z* 176 (M+H).

#### Racemic Mono-*N*-methylvalidamine (5)

A solution of **8** (30 mg) in 97% ethyl formate (4 ml) was heated at reflux for 2 hours. The reaction mixture was evaporated to give racemic *N*-formyl-di-*O*-isopropylidenevalidamine (**10**, 32 mg, 96%) as a colorless foam, which on TLC gave a single spot at R<sub>f</sub> 0.4 (toluene - ethanol, 4 : 1). Without further purification, the product was dissolved in dry THF (8 ml) and the mixture was heated at reflux with lithium aluminum hydride (50 mg) for 7 hours. The excess hydride was destroyed by addition of water and the mixture was evaporated to dryness. The product was chromatographed on a silica gel column eluted with toluene - ethanol (4 : 1). The fractions containing a single spot at R<sub>f</sub> 0.2 (toluene - ethanol, 4 : 1) were combined and evaporated to give racemic mono-*N*-methyl-di-*O*-isopropylidenevalidamine (**11**, 26 mg, 82% from **8**) as a colorless syrup: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.96 (1H, br t, *J*=13.3 Hz, H-6<sub>ax</sub>), 1.37 (3H), 1.38 (6H) and 1.44 (3H) (isopropylidene CH<sub>3</sub>), 1.66 (1H, br d, *J*=ca. 13 Hz, H-6<sub>eq</sub>), 1.95~2.07 (1H, m, H-5), 2.36 (3H, s, NCH<sub>3</sub>), 3.14 (1H, d, *J*=2.8 Hz, H-1), 3.46 (1H, dd, *J*=7.7 and 2.8 Hz, H-2), 3.58~3.74 (3H, m, H-3, H-7a and H-7b), 3.98 (1H, t, *J*=9.5 Hz, H-4).

*Anal* Calcd for C<sub>14</sub>H<sub>26</sub>NO<sub>4</sub>: M<sub>r</sub> 272.1862. Found: M<sub>r</sub> 272.1854 (high resolution FAB-MS (HRFAB-MS)).

Compound **11** (22 mg) was treated with 1 M hydrochloric acid (2 ml) at 70°C for 1 hour. After neutralization with Amberlite IRA 400 (OH<sup>-</sup>) resin, the filtrate was concentrated to give a pale yellow syrup which was purified by column chromatography on Dowex 1-X2 (OH<sup>-</sup>, 100~200 mesh) with water to give **5** (15 mg, 97% from **11**) as a colorless syrup: <sup>1</sup>H NMR (D<sub>2</sub>O) δ 1.11 (1H, td, *J*=14.8 and 3.3 Hz, H-6<sub>ax</sub>), 1.58 (1H, m, H-5), 1.83 (1H, dt, *J*=14.8 and 3.0 Hz, H-6<sub>eq</sub>), 2.16 (3H, s, NCH<sub>3</sub>), 2.81 (1H, br s, H-1), 3.08 (1H, dd, *J*=10.7 and 8.7 Hz, H-4), 3.35 (1H, t, *J*=8.7 Hz, H-3), ca. 3.45 (2H, m, H-2 and H-7a), 3.56 (1H, dd, *J*=11.2 and 3.5 Hz, H-7b).

*Anal* Calcd for C<sub>8</sub>H<sub>18</sub>NO<sub>4</sub>: M<sub>r</sub> 192.1236. Found: M<sub>r</sub> 192.1232 (HRFAB-MS).

#### Racemic Mono-*N*-methylvalienamine (6)

Compound **12** (20 mg) was *N*-formylated with 97% ethyl formate (4 ml) as described for the preparation of **10**. After evaporation, the residual syrup of racemic *N*-formyl-di-*O*-isopropylidenevalienamine (**13**, 22 mg, 99%), giving a single spot at R<sub>f</sub> 0.5 on TLC (toluene - ethanol, 4 : 1), was dissolved in dry THF (8 ml) upon heating. To the solution was added lithium aluminum hydride (40 mg) and the mixture was heated at reflux for 7 hours. The reaction was quenched by addition of water and the mixture was evaporated to dryness. Silica gel column chromatography of the residue with toluene - ethanol (4 : 1) yielded racemic mono-*N*-methyl-di-*O*-isopropylidenevalienamine (**14**, 17 mg, 81% from **12**) as a colorless syrup: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.42 (3H, s), 1.48 (6H, s) and 1.56 (3H, s) (isopropylidene CH<sub>3</sub>), 2.55 (3H, s, NCH<sub>3</sub>), 3.47 (1H, br t, *J*=ca. 4.5 Hz, H-1), 3.65 (1H, dd, *J*=10 and 4.8 Hz, H-2), 4.07 (1H, dd, *J*=10 and 8.0 Hz, H-3), 4.20 (1H, d) and 4.47 (1H, br d) (*J*=14 Hz, H-7a and H-7b), 4.54 (1H, d, *J*=8.0 Hz, H-4), 5.64 (1H, d, *J*=4.5 Hz, H-6).

*Anal* Calcd for C<sub>14</sub>H<sub>24</sub>NO<sub>4</sub>: M<sub>r</sub> 270.1705. Found: M<sub>r</sub> 270.1697 (HRFAB-MS).

Compound **14** (15 mg) was hydrolyzed and the product was purified in the same manner described for the preparation of **5** to give **6** (9.5 mg, 96% from **14**) as a colorless syrup: <sup>1</sup>H NMR (D<sub>2</sub>O) δ 2.24 (3H, s, NCH<sub>3</sub>), 3.18 (1H, t, *J*=4.5 Hz, H-1), 3.61 (1H, dd, *J*=12.0 and 6.0 Hz, H-5), 3.65 (1H, dd, *J*=12.0 and 5.2 Hz, H-6), 3.92 (1H, d, *J*=6.0 Hz, H-4), 3.97 (1H, d) and 4.07 (1H, d) (*J*=13.7 Hz, H-7a and H-7b), 5.73 (1H, dd, *J*=4.5 and 1.3 Hz, H-2).

*Anal* Calcd for C<sub>8</sub>H<sub>16</sub>NO<sub>4</sub>: M<sub>r</sub> 190.1079. Found: M<sub>r</sub> 190.1080 (HRFAB-MS).

## Acknowledgments

This work was supported by a grant from the National Institute of Allergy and Infectious Diseases (AI 01278). The Nicolet NT-360 spectrometer was provided in part by a National Science Foundation grant to the University of Illinois Regional Instrumentation Facility (CHE 79-16100). We thank Dr. M. POTGIETER for helpful discussions, Mr. S. A. MIZSAK for the COSY and 1D 500-MHz <sup>1</sup>H NMR spectra, Professors T. SUAMI and S. OGAWA, Keio University, Yokohama, Japan, for providing samples 8 and 9, and Dr. S. HORII, Takeda Chemical Industries, Ltd., Osaka, Japan, for an authentic sample of validamycin A. We also thank Mr. J. C. COOK for obtaining the mass spectra.

## References

- 1) IWASA, T.; E. HIGASHIDE, H. YAMAMOTO & M. SHIBATA: Studies on validamycins, new antibiotics. II. Production and biological properties of validamycin A and B. *J. Antibiotics* 24: 107~113, 1971
- 2) HORII, S. & Y. KAMEDA: Structure of the antibiotic validamycin A. *J. Chem. Soc. Chem. Commun.* 1972: 747~748, 1972
- 3) SUAMI, T.; S. OGAWA & N. CHIDA: The revised structure of validamycin A. *J. Antibiotics* 33: 98~99, 1980
- 4) OGAWA, S.; T. NOSE, T. OGAWA, T. TOYOKUNI, Y. IWASAWA & T. SUAMI: Synthetic studies on validamycins. Part 11. Synthesis of validamycin A. *J. Chem. Soc. Perkin Trans. I* 1985: 2369~2374, 1985
- 5) HORNEMANN, U.; J. P. KEHRER, C. S. NUNEZ & R. L. RANIERI: D-Glucosamine and L-citrulline, precursors in mitomycin biosynthesis by *Streptomyces verticillatus*. *J. Am. Chem. Soc.* 96: 320~322, 1974
- 6) RINEHART, K. L., Jr. & L. S. SHIELD: Chemistry of the ansamycin antibiotics. *Fortschr. Chem. Org. Naturst.* 33: 231~307, 1976
- 7) RINEHART, K. L., Jr.; M. POTGIETER, W. JIN, C. J. PEARCE, D. A. WRIGHT, J. L. C. WRIGHT, J. A. WALTER & A. G. MCINNES: Biosynthetic studies on antibiotics employing stable isotopes. *In Trends in Antibiotic Research. Genetics, Biosyntheses, Actions & New Substances. Ed., H. UMEZAWA et al., pp. 171~184, Japan Antibiotics Res. Assoc., Tokyo, 1982*
- 8) RINEHART, K. L., Jr.: Newer methods for characterization of antibiotics. I. Stable isotopes in the study of antibiotic biosynthesis. *Bio/Technology* 1: 495~502, 1983
- 9) BOTTO, R. E. & B. COXON: Two-dimensional proton J-resolved NMR spectroscopy of neomycin B. *J. Carbohydr. Chem.* 3: 545~563, 1984
- 10) BAX, A. (Ed.): *Two-Dimensional Nuclear Magnetic Resonance in Liquids.* Delft University Press, Boston, 1984
- 11) ERNST, R. R.: The information content of two-dimensional Fourier spectroscopy. *In NMR Spectroscopy: New Methods and Applications, ACS Symposium Ser. 191. Ed., G. C. LEVY, pp. 47~61, American Chemical Soc., Washington, D.C., 1982*
- 12) JACKMAN, L. M. & S. STERNHELL: Vicinal interproton coupling. *In Applications of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry. 2nd Ed., pp. 286~289, Pergamon Press, New York, 1969*
- 13) ABRAHAM, R. J.; H. GOTTSCHALCK, H. PAULSEN & W. A. THOMAS: The proton magnetic resonance spectra and conformations of cyclic compounds. Part II. The p.m.r. spectra of the conduritols. *J. Chem. Soc.* 1965: 6268~6277, 1965
- 14) NAITO, T.; S. TODA, S. NAKAGAWA & H. KAWAGUCHI: Carbon-13 NMR spectra of aminoglycoside antibiotics. *In Aminocyclitol Antibiotics. ACS Symposium Ser. 125. Eds., K. L. RINEHART, Jr. & T. SUAMI, pp. 257~294, American Chemical Society, Washington, D.C., 1980*
- 15) SARNESKI, J. E.; H. L. SURPRENANT, F. K. MOLEN & C. N. REILLEY: Chemical shifts and protonation shifts in carbon-13 nuclear magnetic resonance studies of aqueous amines. *Anal. Chem.* 47: 2116~2124, 1975
- 16) ROBERTS, J. D.; F. J. WEIGERT, J. I. KROSCWITZ & H. J. REICH: Nuclear magnetic resonance spectroscopy. Carbon-13 chemical shifts in acyclic and alicyclic alcohols. *J. Am. Chem. Soc.* 92: 1338~1347, 1970
- 17) DAVIES, D. H.; A. K. MALLAMS, J. MCGLOTTEN, J. B. MORTON & R. W. TKACH: Structure of aminoglycoside 66-40C, a novel unsaturated imine produced by *Micromonospora inyoensis*. *J. Chem. Soc. Perkin Trans. I* 1977: 1407~1411, 1977
- 18) PEHK, T. & E. LIPPMAN: Carbon-13 chemical shifts of acyclic compounds. *Esti NSV Tead. Akad. Toim., Keem., Geol.* 17: 291~294, 1968 [Chem. Abstr. 70: 15795g, 1969]
- 19) PEHK, T.; S. RANG, O. EISEN & E. LIPPMAN: Carbon-13 chemical shifts of substituted cyclohexenes and

- cyclopentenes. *Esti NSV Tead. Akad. Toim., Keem., Geol.* 17: 296~299, 1968 [Chem. Abstr. 70: 15858e, 1969]
- 20) BOCK, K. & C. PEDERSEN: Carbon-13 nuclear magnetic resonance spectroscopy of monosaccharides. *Adv. Carbohydr. Chem. Biochem.* 41: 27~66, 1983
  - 21) MUNRO, M. H. G.; R. M. STROSHANE & K. L. RINEHART, Jr.: Location of guanidino and ureido groups in bluensomycin from <sup>13</sup>C NMR spectra of streptomycin and related compounds. *J. Antibiotics* 35: 1331~1337, 1982
  - 22) IWASA, T.; Y. KAMEDA, M. ASAI, S. HORII & K. MIZUNO: Studies on validamycins, new antibiotics. IV. Isolation and characterization of validamycins A and B. *J. Antibiotics* 24: 119~123, 1971
  - 23) HORII, S.; Y. KAMEDA & K. KAWAHARA: Studies on validamycins, new antibiotics. VIII. Isolation and characterization of validamycins C, D, E and F. *J. Antibiotics* 25: 48~53, 1972
  - 24) TOYOKUNI, T.; S. OGAWA & T. SUAMI: Synthetic studies on the validamycins. IX. Synthesis of some racemic isomers of validoxylamine A. *Bull. Chem. Soc. Jpn.* 56: 2999~3004, 1983
  - 25) TOYOKUNI, T.; S. OGAWA & T. SUAMI: Synthetic studies on the validamycins. IV. Synthesis of DL-valienamine and related branched-chain unsaturated aminocyclitols. *Bull. Chem. Soc. Jpn.* 56: 1161~1170, 1983